/
/
ASH 2017: Myeloma Patients Need a Flu Shot Booster!
ASH 2017: Myeloma Patients Need a Flu Shot Booster! image
ASH 2017: Myeloma Patients Need a Flu Shot Booster!
Posted Dec 10, 2017

Researchers found in a study called the “Shivering 2 Trial” during last year’s flu season, that persons with plasma cell disorders, i.e.multiple myeloma, do not get much protection from the flu even after getting the high dose shot.  When we have compromised immunity to start with and are often older, or have other health challenges, our bodies are set up for a weaker, shorter-term responses to the vaccine.  Though we need six months of full immunity to be protected through a normal flu season, myeloma patients start losing their seroprotection early, some after just one month. The study was described at an ASH presentation by Dr. Andrew Branagan as follows:

Forty-eight patients received a single standard of care influenza vaccination and 74 patients received two doses of Fluzone High-Dose vaccine. Median age was 67 years (range 42-90). Following the second vaccine, rates of total seroprotection (against all 3 influenza vaccine strains) were 86.3% for patients who received two high dose vaccines and 63.9% for standard vaccination patients. At the end of the flu season, rates of total seroprotection were 58.5% for patients who received two high dose vaccines and 33.3% for standard vaccination patients. Those patients who had a lower likelihood of serologic response to the flu vaccine were those who were older, male, had a remission status less than partial response and/or were receiving alkylating agent chemotherapy. The second vaccination was given at 30 days after the first and was well-tolerated.

All of which begs the question, what might this mean for all the other immunizations MM patients get---particularly after ASCT? Dr. Branagan urged more study for dosing and timing of flu vaccinations with the thought that it may result in practice-changing implications for other vaccines and therapies going forward.

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811